Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma

Cancer Science

Volumn 103, Issue 5, 2012, Pages 933-938

  Ogura, Michinori ^a   Hatake, Kiyohiko ^b   Ando, Kiyoshi ^c   Tobinai, Kensei ^d   Tokushige, Kota ^e   Ono, Chiho ^e   Ishibashi, Taro ^e   Vandendries, Erik ^e  

^a NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c TOKAI UNIVERSITY HOSPITAL   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; INOTUZUMAB OZOGAMICIN; LACTATE DEHYDROGENASE; RITUXIMAB;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; DECREASED APPETITE; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FOLLICULAR LYMPHOMA; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERBILIRUBINEMIA; HYPOPHOSPHATEMIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MANTLE CELL LYMPHOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REFRACTORY B CELL NONHODGKIN LYMPHOMA; RHINOPHARYNGITIS; SIDE EFFECT; STOMATITIS; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD22; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEUTROPENIA; RECURRENCE;

EID: 84860243682     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02241.x     Document Type: Article

References (19)

1. Leonard JP, Coleman M, Ketas JC et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res 2004; 10: 5327-34.
2. DiJoseph JF, Armellino DC, Boghaert ER et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 2004; 103: 1807-14.
3. DiJoseph JF, Khandke K, Dougher MM et al. CMC-544 (inotuzumab ozogamicin): a CD22-targeted immunoconjugate of calicheamicin. Hematol Meet Rep 2008; 5: 74-7.
4. DiJoseph JF, Goad ME, Dougher MM et al. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin Cancer Res 2004; 10: 8620-9.
5. DiJoseph JF, Dougher MM, Kalyandrug LB et al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin Cancer Res 2006; 12: 242-9.
6. Rituxan (rituximab) Injection for Intravenous Use (package insert). South San Francisco, CA: Biogen Idec Inc. and Genentech, Inc., 2011.
7. Davis TA, Grillo-Lopez AJ, White CA et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18: 3135-43.
8. Czuczman MS, Olejniczak S, Gowda A et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res 2008; 14: 1561-70.
9. Leonard JP, Martin P. Novel agents for follicular lymphoma. Hematology Am Soc Hematol Educ Program 2010; 2010: 259-64.
10. Advani A, Coiffier B, Czuczman MS et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010; 28: 2085-93.
11. Ogura M, Tobinai K, Hatake K et al. Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Cancer Sci 2010; 101: 1840-5.
12. Dang NH, Smith MR, Offner F et al. Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: clinical activity including survival in patients with recurrent/refractory follicular or 'aggressive' lymphoma. Blood 2009; 114: Abstract 584.
13. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House: Virginia, November, 1997. J Clin Oncol 1999; 17: 3835-49.
14. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
15. Golay J, Manganini M, Facchinetti V et al. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica 2003; 88: 1002-12.
16. Pfreundschuh M, Trumper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-91.
17. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-33.
18. Leonard JP, Schuster SJ, Emmanouilides C et al. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 2008; 113: 2714-23.
19. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93: 2645-68.